Squarepoint’s Viking Therapeutics VKTX Stock Holding History

Squarepoint’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,300	Closed	-$400K	–	5031
2026 Q1	$400K	Sell	12,300 -46,600	-79%	-$1.5M	﹤0.01%	3487
2025 Q4	$2.07M	Sell	58,900 -22,800	-28%	-$808K	﹤0.01%	2037
2025 Q3	$2.15M	Buy	+81,700	New	+$2.44M	﹤0.01%	2037
2025 Q2	–	Sell	-167,000	Closed	-$4.03M	–	5104
2025 Q1	$4.03M	Buy	167,000 +118,700	+246%	+$3.75M	﹤0.01%	1571
2024 Q4	$1.94M	Buy	48,300 +25,300	+110%	+$1.44M	﹤0.01%	2449
2024 Q3	$1.46M	Sell	23,000 -12,000	-34%	-$704K	﹤0.01%	2314
2024 Q2	$1.86M	Buy	+35,000	New	+$2.29M	﹤0.01%	2104

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Squarepoint's VKTX Position: Q2 2026 in Review

Squarepoint opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 41,139 shares worth $1.6M. The stake represents ﹤0.01% of the portfolio and ranks #2512 among its holdings. This is a return to the name: Squarepoint previously reported a position in VKTX as recently as Q2 2025.

Squarepoint first reported a position in VKTX in Q4 2018 and has held it in 23 quarters since. The position peaked at $10.8M in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Squarepoint held 41,139 shares of Viking Therapeutics worth $1.6M as of Q2 2026.
Viking Therapeutics was a new Squarepoint position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2512 holding.
Squarepoint first reported a position in Viking Therapeutics in Q4 2018 and has held it in 23 quarters since.
Squarepoint's Viking Therapeutics position peaked at $10.8M in Q4 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.